BioCentury | Apr 6, 2009
Company News

Genaera endocrine, inflammation news

...MedImmune Inc., a subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) is developing MEDI-528, and MacroChem Corp....
BioCentury | Dec 22, 2008
Clinical News

Pexiganan: Phase III data

...a 46% response rate vs. 47% for ofloxacin. Data were published in Clinical Infectious Diseases. MacroChem...
...an exclusive, worldwide license to pexiganan from Genaera. In July, Access announced a merger with MacroChem...
...BioCentury, July 14). Access Pharmaceuticals Inc. (OTCBB:ACCP), Dallas, Texas Genaera Corp. (NASDAQ:GENR), Plymouth Meeting, Pa. MacroChem Corp....
BioCentury | Dec 22, 2008
Clinical News

Pexiganan: Phase III data

...of development of resistance during treatment with pexiganan. Data were published in Clinical Infectious Diseases. MacroChem...
...an exclusive, worldwide license to pexiganan from Genaera. In July, Access announced a merger with MacroChem...
...BioCentury, July 14). Access Pharmaceuticals Inc. (OTCBB:ACCP), Dallas, Texas Genaera Corp. (NASDAQ:GENR), Plymouth Meeting, Pa. MacroChem Corp....
BioCentury | Jul 28, 2008
Clinical News

EcoNail: Phase II data

...area. Also, 8 patients met the study's secondary endpoint of negative mycology at 48 weeks. MacroChem Corp....
BioCentury | Jul 14, 2008
Company News

Access Pharmaceuticals, MacroChem deal

...Access will acquire MacroChem for 2.5 million shares valued at $8 million based on Access’ close...
...9, the day before the deal was announced. The deal gives Access full rights to MacroChem’s...
...leukemia and advanced prostate cancer and which was already partnered with Access. Access also gets MacroChem’s...
BioCentury | Apr 28, 2008
Company News

MacroChem board of directors update

MacroChem Corp. (OTCBB:MACM), Wellesley Hills, Mass. Business: Drug delivery, Infectious, Genitourinary Resigned: John Zabriskie; Michael Davis; Peter Martin; and Paul Echenberg WIR Staff Genitourinary Infectious...
BioCentury | Apr 28, 2008
Company News

MacroChem management update

MacroChem Corp. (OTCBB:MACM), Wellesley Hills, Mass. Business: Drug delivery, Infectious, Genitourinary Hired: James Pachence as CEO and a director, formerly president and CEO of Virium Pharmaceuticals Inc. Transitioned: David Luci to president, CBO, COO and...
BioCentury | Apr 28, 2008
Company News

MacroChem, Virium deal

...a topical anti-infective that has completed two Phase III trials to treat diabetic foot infection. MacroChem...
...2007, MacroChem had $3.2 million in cash and a full-year operating loss of $5.9 million. MacroChem Corp....
...Drug delivery MacroChem acquired Virium for 22.9 million shares valued at $6.9 million based on MacroChem's...
BioCentury | Mar 24, 2008
Company News

MacroChem management update

MacroChem Corp. (OTCBB:MACM), Wellesley Hills, Mass. Business: Drug delivery, Infectious, Genitourinary Transitioned: David Luci to CFO while remaining general counsel and VP of corporate development; he replaces Bernard Patriacca, who retired WIR Staff Genitourinary Infectious...
BioCentury | Dec 10, 2007
Company News

MacroChem management update

MacroChem Corp. (MACM), Wellesley Hills, Mass. Business: Drug delivery, Infectious, Genitourinary Hired: David Luci as general counsel, corporate secretary and VP of corporate development, formerly general counsel and EVP at Bioenvision Inc. WIR Staff Genitourinary...
Items per page:
1 - 10 of 118
BioCentury | Apr 6, 2009
Company News

Genaera endocrine, inflammation news

...MedImmune Inc., a subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) is developing MEDI-528, and MacroChem Corp....
BioCentury | Dec 22, 2008
Clinical News

Pexiganan: Phase III data

...a 46% response rate vs. 47% for ofloxacin. Data were published in Clinical Infectious Diseases. MacroChem...
...an exclusive, worldwide license to pexiganan from Genaera. In July, Access announced a merger with MacroChem...
...BioCentury, July 14). Access Pharmaceuticals Inc. (OTCBB:ACCP), Dallas, Texas Genaera Corp. (NASDAQ:GENR), Plymouth Meeting, Pa. MacroChem Corp....
BioCentury | Dec 22, 2008
Clinical News

Pexiganan: Phase III data

...of development of resistance during treatment with pexiganan. Data were published in Clinical Infectious Diseases. MacroChem...
...an exclusive, worldwide license to pexiganan from Genaera. In July, Access announced a merger with MacroChem...
...BioCentury, July 14). Access Pharmaceuticals Inc. (OTCBB:ACCP), Dallas, Texas Genaera Corp. (NASDAQ:GENR), Plymouth Meeting, Pa. MacroChem Corp....
BioCentury | Jul 28, 2008
Clinical News

EcoNail: Phase II data

...area. Also, 8 patients met the study's secondary endpoint of negative mycology at 48 weeks. MacroChem Corp....
BioCentury | Jul 14, 2008
Company News

Access Pharmaceuticals, MacroChem deal

...Access will acquire MacroChem for 2.5 million shares valued at $8 million based on Access’ close...
...9, the day before the deal was announced. The deal gives Access full rights to MacroChem’s...
...leukemia and advanced prostate cancer and which was already partnered with Access. Access also gets MacroChem’s...
BioCentury | Apr 28, 2008
Company News

MacroChem board of directors update

MacroChem Corp. (OTCBB:MACM), Wellesley Hills, Mass. Business: Drug delivery, Infectious, Genitourinary Resigned: John Zabriskie; Michael Davis; Peter Martin; and Paul Echenberg WIR Staff Genitourinary Infectious...
BioCentury | Apr 28, 2008
Company News

MacroChem management update

MacroChem Corp. (OTCBB:MACM), Wellesley Hills, Mass. Business: Drug delivery, Infectious, Genitourinary Hired: James Pachence as CEO and a director, formerly president and CEO of Virium Pharmaceuticals Inc. Transitioned: David Luci to president, CBO, COO and...
BioCentury | Apr 28, 2008
Company News

MacroChem, Virium deal

...a topical anti-infective that has completed two Phase III trials to treat diabetic foot infection. MacroChem...
...2007, MacroChem had $3.2 million in cash and a full-year operating loss of $5.9 million. MacroChem Corp....
...Drug delivery MacroChem acquired Virium for 22.9 million shares valued at $6.9 million based on MacroChem's...
BioCentury | Mar 24, 2008
Company News

MacroChem management update

MacroChem Corp. (OTCBB:MACM), Wellesley Hills, Mass. Business: Drug delivery, Infectious, Genitourinary Transitioned: David Luci to CFO while remaining general counsel and VP of corporate development; he replaces Bernard Patriacca, who retired WIR Staff Genitourinary Infectious...
BioCentury | Dec 10, 2007
Company News

MacroChem management update

MacroChem Corp. (MACM), Wellesley Hills, Mass. Business: Drug delivery, Infectious, Genitourinary Hired: David Luci as general counsel, corporate secretary and VP of corporate development, formerly general counsel and EVP at Bioenvision Inc. WIR Staff Genitourinary...
Items per page:
1 - 10 of 118